In this review:
Endocrine therapy +/- chemotherapy for BC
Metformin in early BC
Adjuvant palbociclib in HoR+/HER2- early BC
Aromatase inhibitors in oestrogen receptor-positive early BC
Exemestane + OFS for HoR-positive early BC
KEYNOTE-522: Pembrolizumab in early-stage triple-negative BC
Taxane with vs without anthracycline for early-stage BC
Elacestrant for metastatic BC after progression on endocrine therapy
KEYNOTE-355: Pembrolizumab in inoperable or metastatic triple-negative BC
Datopotamab deruxtecan in advanced/ metastatic HER2-negative BC
Please login below to download this issue (PDF)